A New Combination of Idarubicin, Etoposide and Cytarabine in Untreated Acute Non-Lymphoblastic Leukemia

References

• Weinstein Mayer H. J., Rosenthal R. J. D., Coral F. S., Camitta R. M., Gelber R. D. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood. 1983; 62: 315–19
   PubMed Web of Science ®Google Scholar
• Baehner Bernstein R. L., Sather I. D.H., et al. Contrasting benefits of two maintenance programs following identical induction in children with acute nonlymphocytic leukemia: a report from the Children's Cancer Study Group. Cancer Treat Rep. 1984; 68: 1269–72
   PubMedGoogle Scholar
• Creutzig Ritter U., Riehm J.H., et al. Contrasting benefits of two maintenance programs following identical induction in children with acute nonlymphocytic leukemia: a report from the Children's (Cancer Study Group. Cancer Treat Rep. 1984; 68: 1269–71
   PubMedGoogle Scholar
• Dahl Kalwnsky E. V.D.K., Mirro J. Look at a comparison of cytokinetically based versus intensive chemotherapy for childhood acute myelogenous leukemia. Hematology and Blood Transfusion 1987; 30: 83–87
   PubMedGoogle Scholar
• Amadori Ceci S., Comelli A.A. Treatment of acute myelogenous leukemia in children. Results of the Italian Cooperative Study AIEOP/LAM 8204. J. Clin. Oncol. 1987; 5: 1356–63
   PubMed Web of Science ®Google Scholar
• Grier Gelber H. E., Camitta R. D.B.M., et al. Prognostic factors in (childhood acute myelogenous leukemia. J. Clin Oncol 1987; 5: 1026–32
   PubMed Web of Science ®Google Scholar
• Woods Ruymann W. G., Lampkin F. B.B.C., et al. Aggressive intensification treatment may abrogate the need for maintenance therapy in children with acute non-lymphocytic leukemia. Blood 1987; 70((Suppl. 1))241a
   Google Scholar
• Berman Arlin E., Gaynor Z. A., Miller J., Gee W., Kempin T., Mertelsmann J., Andreef R., Reich M., Nahmias L.N., Clarkson B. (Comparative trial of Cytarabine and Thioguanine in Combination with Amsacrine: or Daunorubicin in patients with untreated acute non lymphocytic leukemia: Results of the L-16M Protocol. Leukemia 1989; 3: 115–21
   PubMed Web of Science ®Google Scholar
• Sauter Berchtold C., Fopp W.M., et al. Acute myelowgenous leukemia: maintenance chemotherapy after early consolidation treatments does not prolong survival. Lancet 1984; 379–82
   PubMed Web of Science ®Google Scholar
• Cassileth Begg P. A., Bennet C. B.J.M., et al. randomized study of the efficacy of consolidation therapy in acute nonlymphocytic leukemia. Blood 1984; 63: 843–47
   PubMed Web of Science ®Google Scholar
• Vogler Winton W. R., Gordon F. F.D.S., et al. A randomized comparison of post remission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial. Blood 1984; 63: 1039–45
   PubMed Web of Science ®Google Scholar
• Mayer R.J., Schiffer C. A., Peterson B. A., et al. Intensive post remission therapy in adults with acute non lymphocytic leukemia with AKA-C by continuous infusion or bolus administration: preliminary results of a CAILGB phase A study. Sem. Oncology. 1935; 12: 84–90
   Google Scholar
• Herzig Lazarus R. H., Wolff H. M., Phillips S. N.G.L., Herzig G. L. High dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute non-lymphoblatic leukemia. J. Clin Oncol. 1985; 3: 992–97
   PubMed Web of Science ®Google Scholar
• Buchner Urbanitz T., Hiddemann D.W., et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AMI): two multicenter studies of the German AML cooperative group. J. Clin Oncol 1985; 3: 1583–89
   PubMed Web of Science ®Google Scholar
• Rees Gray J. K. H., Swirsky R. G.D., Heyhoe F. G. J. Principal results of the Medical Research Council's 8th acute myeloid leukemia trial. Lancet 1986; ii: 1236–41
   Google Scholar
• Preisler Davis H., Kirshner R. B.J. Comparison of three remission induction regimens and two post induction strategies for the treatment of acute nonlymphocytic leukemia. A cancer and Leukemia Group B Study. Blood 1987; 69: 144–49
   PubMedGoogle Scholar
• Mandelli Petti F.M.C., Spiriti M. A. Acute non lymphoid leukemia treatment: an update. Haematologica 1988; 72: 1–6
   Google Scholar
• Butturini Gale A.R.P. Chemotherapy versus transplantation in acute leukemia. Brit. J. Haematol. 1989; 72: 1–8
   PubMed Web of Science ®Google Scholar
• Arcamone Bernardi F. L., Giordano L.R.P. Synthesis and antitumor activity of 4–DMDR and their beta anomers. Cancer Treat. Rep. 1976; 60: 829–34
   PubMedGoogle Scholar
• Casazza Pratesi A. M., Giuliani G.F., Di Marco A. Antileukemic activity of 4–demethoxy-daunorubicin in mice. Tumori 1980; 66: 549–64
   PubMedGoogle Scholar
• Carella Santini A. M., Martinengo G., Giordano M., Cerri D., Risso R., Nati M., Rossi S., Marmont E.A.M. 4–demethoxydauno-rubicin (idarubicin) in refractory or relapsed acute leukemia. A pilot study. Cancer 1985; 55: 1452–54
   PubMed Web of Science ®Google Scholar
• Bacigalupo Frassoni A., VanLint F., Marmont M. T.A.M. Bone marrow transplantation for acute non lymphoblastic leukemia (ANLL) in first remission. Acta Haematol 1985; 74: 23–26
   PubMed Web of Science ®Google Scholar
• Burke Karp P. J., Geller J. E.R.B. Cures of Leukemia with aggressive postremission treatment: an update of timed sequential therapy (AC-D-AC). Leukemia 1989; 10: 692–94
   Google Scholar
• Wolff Herzig S. N., Fay R. H.J.W. High-dose cytarabine and Daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: Long-term follow-up and results. J. Clin. Oncol. 1989; 9: 1260–67
   Google Scholar
• Carella Berman A. M., Ganzina E.F. Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies. Haematologica, (in press)
   PubMedGoogle Scholar
• Berman Raymond E., Gee V.T. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center. Sem. Oncol. 1989; 16(1)(Suppl. 2)30–34
   Google Scholar
• Wiernik Case P. H., Periman D.P.O. A multicenter trial of Cytarabine plus Idarubicin or Daunorubicin as induction therapy for adult acute non-lymphocytic leukemia. Sem. Oncol. 1989; 16(1)(Suppl. 2)25–29
   Google Scholar
• Vogler Velez-Garcia W. R., Omura E.G. A phase three trial comparing Daunorubicin or Idarubicin combined with Cytosine Arabinoside in acute myelogenous leukemia. Sem. Oncol. 1989; 16(1)(Suppl. 2)21–24
   Google Scholar
• Petti Mandelli M. C.F. Idarubicin in acute leukemias: Experience of the Italian Cooperative Group GIMEMA. Sem. Oncol. 1989; 16(1)(Suppl. 2)10–15
   Google Scholar
• Reiffers Hurtecoupe J., Stoppa P.A.M., et al. A prospective controlled study comparing Idarubicin and Daunorubicin in induction treatment for acute non-lymphoblastic leukemia in the elderly. Haematologica 1988; 73((suppl.))126
   Google Scholar
• Bloomfield C. D. Postremission therapy in acute myeloid leukemia. J. Clin. Oncol. 1985; 3: 1570–72
   PubMed Web of Science ®Google Scholar
• Keating M. J., Smith T. L., McCredie K. B. A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer 1981; 47: 2779–88
   PubMed Web of Science ®Google Scholar
• Bern Cloud M. M., Corkey L. P.J.C. Age and treatment of acute non lymphoblastic leukemia. N. Engl. J. Med 1981; 305: 642–43
   PubMed Web of Science ®Google Scholar
• Naparstek Zajicek E., Or G., Rachmilewits R.E A., Polliack A., Elias M. Results of therapy in adult acute non lymphoblastic leukemia: experience in Jerusalem. Israel, during 1975 1982. Acta Haematol 1985; 73: 11–15
   Google Scholar
• Foon Zighelboim K. A.J. Intensive chemotherapy in the treatment of choice for elderly patients with acute myelogenous leukemia. Blood 1981; 58: 467–69
   PubMed Web of Science ®Google Scholar
• Kanh Ebrahim S. B., Cassileth K., Bennett P.J.M. Alternated high-dose Cytosine Arabinoside in the treatment of the elderly patient with acute non lymphoblastic leukemia. Am. J. Clin. Oncol. 1989; 12: 201–04
   PubMed Web of Science ®Google Scholar